AbbVie (ABBV) IV into FDA decision on Rinvoq

October 18, 2021 5:01 AM EDT

AbbVie (NYSE: ABBV) 30-day option implied volatility is at 23; compared to its 52-week range of 18 to 40 into FDA decision on Rinvoq.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Options

Related Entities

Options, FDA